The treatment cost for the newest hep C drugs have dropped dramatically since they were introduced. Started around $100,000 for a course. So six-figure price tags don't keep "cure"-level drugs from getting approved or introduced. The cost of the existing not-a-cure treatments also added up fast, after all; as they do for many cancers.

You're right about the specificity - Hep C is a bigger-population target than a lot of cancers are - but a lot of the new approaches are looking to be inherently more "personalized" to compensate.